Dr. Lee on Choosing Among Antiandrogens in Nonmetastatic CRPC

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).

When choosing among apalutamide (Erleada), enzalutamide (Xtandi), and darolutamide, the differing hazard ratios for benefit will be considered, as well as the differing safety profiles of the drugs in CRPC, says Lee. Certainly, other aspects can also be considered, such as the financial toxicity of these therapies, but these categories of drugs seem to be similarly priced with a similar impact upon patients, adds Lee. It is unclear where darolutamide, the newest addition of the three agents, will fit into the treatment paradigm. The other drugs have had a head start in that they already have established use in practice, concludes Lee.